Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-25 · accession 0001104659-24-123807 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-27 | 2024-11-25+ | PTGX | Gupta Suneel | Chief Development Off | S - Sale+OE | $45.96 | -122.6K | 256.2K | -32% | -$5.64M |
| DM | 2024-11-27 | 2024-11-25+ | PTGX | Gupta Suneel | Chief Development Off | M - OptEx | $8.40 | +205.4K | 267.4K | +331% | +$1.73M |
| DM | 2024-11-27 | 2024-11-25+ | PTGX | Gupta Suneel | Chief Development Off | M - OptEx | $0.00 | -205.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-26 | S | D | 19,191 | $45.50 | 266,983 | D | — | — | (F4) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-11-26 | M | A | 30,000 | $12.17 | 286,174 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-25 | S | D | 103,437 | $46.04 | 256,174 | D | — | — | (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2024-11-25 | M | A | 85,000 | $7.80 | 359,611 | D | — | — | |
| 5 | Common | Common Stock | 2024-11-25 | M | A | 45,000 | $8.02 | 274,611 | D | — | — | |
| 6 | Common | Common Stock | 2024-11-25 | M | A | 45,000 | $7.38 | 229,611 | D | — | — | (F1) Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024. |
| 7 | Common | Common Stock | 2024-11-26 | M | A | 450 | $12.17 | 267,433 | D | — | — | |
| 8 | Derivative | Stock Option (right to buy) | 2024-11-26 | M | D | 450 | $0.00 | 93,300 | D | $12.17 · — to 2033-01-15 | 450 Common Stock | (F6) The stock option vests in 48 equal monthly installments following the date of grant. |
| 9 | Derivative | Stock Option (right to buy) | 2024-11-26 | M | D | 30,000 | $0.00 | 93,750 | D | $12.17 · — to 2033-01-15 | 30,000 Common Stock | (F6) The stock option vests in 48 equal monthly installments following the date of grant. |
| 10 | Derivative | Stock Option (right to buy) | 2024-11-25 | M | D | 85,000 | $0.00 | 0 | D | $7.80 · — to 2030-02-27 | 85,000 Common Stock | (F5) These stock options are fully vested. |
| 11 | Derivative | Stock Option (right to buy) | 2024-11-25 | M | D | 45,000 | $0.00 | 0 | D | $8.02 · — to 2029-02-27 | 45,000 Common Stock | (F5) These stock options are fully vested. |
| 12 | Derivative | Stock Option (right to buy) | 2024-11-25 | M | D | 45,000 | $0.00 | 0 | D | $7.38 · — to 2029-01-14 | 45,000 Common Stock | (F5) These stock options are fully vested. |